$MNKD That PR is huge. For an executive to leave Lilly, the largest insulin manufacturer in the world, to go to a small competitor speaks volumes! The clinical data on MNKD's insulin treatment system is incredible.
Closest release profile to the natural pancreatic release of any insulin on the market. Diabetes will be the #1 health concern in the US by 2020.
If you don't have a set of these you best put your money in a CD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.